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Neuronal PAS domain protein 3 (NPAS3) and VGF (VGF Nerve Growth Factor (NGF)
Inducible) are important for neurogenesis and psychiatric disorders. Previously, we
have demonstrated that NPAS3 regulates VGF at the transcriptional level. In this
study, VGF (non-acronymic) was found regulated by NPAS3 in neuronal stem cells.
However, the underlying mechanism of this regulation remains unclear. The aim of this
study was to explore the correlation of NPAS3 and VGF, and their roles in neural cell
proliferation, in the context of psychiatric illnesses. First, we focused on the structure
of NPAS3, to identify the functional domain of NPAS3. Truncated NPAS3 lacking
transactivation domain was also found to activate VGF, which suggested that not only
transactivation domain but other structural motifs were also involved in the regulation.
Second, Mutated enhancer box (E-box) of VGF promoter showed a significant response
to this basic helix-loop-helix (bHLH) transcription factor, which suggested an indirect
regulatory mechanism for controlling VGF expression by NPAS3. κB site within VGF
promoter was identified for VGF activation induced by NPAS3, apart from direct
binding to E-box. Furthermore, ectopically expressed NPAS3 in PC12 cells produced
parallel responses for nuclear factor kappa-light-chain-enhancer of activated B cells
[NF-κB (P65)] expression, which specifies that NPAS3 regulates VGF through the NF-κB
signaling pathway. Over-expression of NPAS3 also enhances the cell proliferation,
which can be blocked by knockdown of VGF. Finally, NPAS3 was found to influence
proliferation of neural cells through VGF. Therefore, downstream signaling pathways
that are responsible for NPAS3-VGF induced proliferation via glutamate receptors were
explored. Combining this work and published literature, a potential network composed
by NPAS3, NF-κB, Brain-Derived Neurotrophic Factor (BDNF), NGF and VGF, was
proposed. This network collectively detailed how NPAS3 connects with VGF and
intersected neural cell proliferation, synaptic activity and psychiatric disorders.
Keywords: NPAS3, VGF, cell proliferation, transcription regulation, neurogenesis, psychiatric disorders,
glutamatergic signaling pathways
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INTRODUCTION
Neuronal PAS domain protein 3 (NPAS3) encodes a member
of the basic helix-loop-helix (bHLH) PAS domain transcription
factor family that typically integrates environmental signals and
binds with heterodimeric partner to generate a transcriptional
response (Brunskill et al., 1999; Gilles-Gonzalez and Gonzalez,
2004). Disruption of the NPAS3 gene carried by a Scottish
mother and daughter diagnosed with schizophrenia and mild
learning disability provided the first indication of the role of this
gene in psychiatric illness (Kamnasaran et al., 2003). Various
gene specific and genome-wide case-control association studies
have linked single nucleotide polymorphisms in the NPAS3
gene with increased risk of schizophrenia, major depression
and bipolar disorder (Pickard et al., 2009; Huang et al.,
2010; Yu et al., 2014). NPAS3 protein is also involved in
other processes in the brain such as neurogenesis, circadian
rhythm and cell proliferation. Npas3 knockout mice display
a range of behavioral phenotypes consistent with it being a
representative model of human psychiatric disorders (Sha et al.,
2012). NPAS3 knockout mice also display an additional deficit
in adult hippocampal neurogenesis and aberrations in synaptic
transmissions (Pieper et al., 2005, 2010), but the underlying
mechanism of dysfunctions of neurogenesis and synaptic activity
in relation to the pathology of psychiatric disorder is currently
unknown.
Similar to NPAS3, VGF plays a major role in depression
(Cattaneo et al., 2010), bipolar disorder (Thakker-Varia et al.,
2010) and schizophrenia (Busse et al., 2012; Ramos et al.,
2014). Studies in mice have produced compelling evidence
that VGF mediates the connection between physical activities,
amplified adult neurogenesis and attenuation of depression-like
phenotypes. VGF and other neuropeptides such as secretogranin
II and neuropeptide Y (NPY) are regulated in the hippocampus
when voluntary exercise was employed as a mood stimulator.
It was also reported that VGF peptide can produce a robust
antidepressant response in a dose dependent manner in
follistatin (FST) and tail suspension trials (Hunsberger et al.,
2007). VGF was reported as an important factor in the central
nervous system in a peptidomic analysis on normal cerebrospinal
fluid (CSF; Yuan and Desiderio, 2005; Spellman et al., 2015).
In addition, TLQP-62, one of the mature peptides of VGF, was
found to specifically enhance the generation of early progenitor
cells in mice (Thakker-Varia et al., 2014). On the whole, these
studies suggest a positive role of VGF in neurogenesis and
connections of VGF in psychiatric disorders.
VGF enhances proliferation of neurogenesis in the adult
hippocampus, and this process requires synaptic activity
(Thakker-Varia et al., 2014). The specific reporters they
identified for VGF-induced neurogenesis, includes N-methyl
D-aspartate receptor (NMDA receptor) and metabotropic
glutamate receptor 5 (mGluR5). mGluR5 mutant mice have
reduced proliferation and differentiation of neuronal progenitors
(Xiao et al., 2013). Activation of mGluR5 induced the
phosphorylation of Protein kinase D (PKD) in hippocampus
neurons (Krueger et al., 2010) and in neural progenitor cells
(Thakker-Varia et al., 2014). PKD modulates DNA synthesis
and cell proliferation in various cell lines (Wong and Jin, 2005)
and has anti-apoptic properties in tumor cells (Trauzold et al.,
2003).
The role of NMDA in neurogenesis has also been
documented. Elevated levels of NMDA or its subunit
enhanced neurogenesis of animal models (Kalev-Zylinska
et al., 2009; Marx et al., 2011; Sharma et al., 2012; Ren et al.,
2013). Furthermore, reduced expression of NMDA produced
impaired neurogenesis of the dentate gyrus in mice (Sha et al.,
2013). Finally, deletion of NMDA subunit (NR2B) impairs a
neurogenesis-dependent form of LTP (Kheirbek et al., 2012).
Ca2+/calmodulin-dependent protein kinase II (CaMKII) was
found to be associated with NMDA receptors and obtains
its activation form by phosphorylation (Bayer et al., 2001).
Mice with mutant CaMKII have immature granule cells in the
dentate gyrus (Yamasaki et al., 2008). Moreover, administration
Dehydroepiandrosterone (DHEA), a steroid receptor agonist,
to olfactory bulbectomized mice increases synaptic efficacy and
neurogenesis in the hippocampal dentate gyrus by activating
CaMKII.
Our previous work investigated the function of NPAS3 at
the transcriptional level, and VGF was found to be the most
up-regulated gene by NPAS3 (Sha et al., 2012). Although VGF
is highly relevant to NPAS3, the way these two factors correlate
has not been well explored.
In this study, we found that the transcription and expression
of VGF is regulated by NPAS3 in neural stem cells (NSCs).
However, the underlyingmechanism remains unclear. Therefore,
the correlation of NPAS3 and VGF and the roles of these
two proteins during neural cell proliferation were the key
questions addressed in this study. For that, we focused on
three aspects: first, we focused on the structure of NPAS3, to
identify the functional domain of NPAS3 by comparing the
reputational activities of different NPAS3 domains on VGF
promoter. Regulation of VGF by dNPAS3, a truncated form
NPAS3 lacking transactivation domain, was compared with
wild type NPAS3. Second, several mutated VGF promoters
were compared to identify the specific regulatory elements
involved in transactivation of NPAS3. Finally, we suspect that
NPAS3 might influence proliferation of neural cells through
VGF. Therefore, proliferation of neural cells was examined. In
addition, in order to understand the relationship of NPAS3-
VGF-prolifaration, one must observe the key changes that occur
during proliferation of neural cells, which are the changes in
glutamate receptors. Downstream signaling pathways that are
responsible for NPAS3-VGF induced proliferation via glutamate
receptors were also explored.
MATERIALS AND METHODS
Plasmids Used in this Study
The NPAS3 open reading frame (acc. NM_001164749) and the
truncated form, dNPAS3, cloned into pcDNA 3.1 expression
plasmid were gifted by Dr. Ben Pickard (University of
Strathclyde, UK). dNPAS3 was generated by deleting the second
PAS domain and the putative transactivation domain.
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TABLE 1 | Four suitable small hairpin RNA (shRNA) target sequences for Neuronal PAS domain protein 3 (NPAS3).

















Four suitable small hairpin RNA (shRNA) target sequences
were selected in the human NPAS3 sequence (Table 1).
All shRNA plasmids were constructed and sequenced by
GenePharma Co., Ltd. (Shanghai, China). Each plasmid was
constructed by inserting a shRNA of human NPAS3 into
a pGPU-GFP-neo vector. Negative controls (NCs) were also
provided. The most efficient shRNA plasmid was selected by
quantitative real-time PCR (qPCR).
Cell Culture and Transient Transfection of
SH-SY5Y, 293T Cells and PC-12 Cells
The HEK-293T embryionic kidney cell line was cultured
in DMEM medium (Gibco) supplemented with 10% fetal
bovine serum (FBS). The SH-SY5Y human neuroblastoma cells
(SH-SY5Y cells) were cultured in RPMI medium 1640 (Gibco)
with 10% FBS. The rat PC-12 pheochromocytoma cells were
cultured in RPMI medium 1640 (Gibco) with 5%FBS and
10% horse serum. Cells were transfected with corresponding
plasmids using Lipofectamine 3000 (Invitrogen) according to the
manufacturer’s instructions.
Dual Luciferase Assay
Human VGF promoters of different sizes (2029 bp, 1237 bp
and 990 bp) were amplified by PCR and cloned into digested
pGL3 reporter vectors. Site-directed mutagenesis was carried
out using Fast Mutagenesis System (TransGen Biotech Co.,
Ltd., Beijing, China). Sequences were confirmed by sequencing
analysis. 293T cells were harvested at 24 h after transfection
for luciferase assay. The activities of Firefly luciferase (expressed
from all pGL3 reporter vectors) and Renilla luciferase (expressed
from co-transfected pRL-TK vector) were examined sequentially
from each sample by using the Dual luciferase Assay kit
(Promega, Madison, WI, USA) with the Plate-reader (Synergy
HT, BioTek, Potton, UK). For each sample, the Firefly luciferase
activity was normalized by the Renilla luciferase activity. The
results were statistically analyzed using SigmaPlot© (Bruxton,
Seattle, WA, USA).
Western Blotting
Cells were solubilized in RIPA lysis buffer containing protease
and phosphatase inhibitors. Protein concentrations were
determined using the BCA Protein Quantitation Assay
Kit (KeyGEN, China). Proteins were separated on a 10%
SDS-polyacrylamide gels and transferred to a polyvinylidene
difluoride (PVDF) membrane. Membranes were probed
with anti-NPAS3 antibody (1:1000, Abcam, Cambridge, MA,
USA), anti-VGF antibody (1:1000, Abcam, Cambridge, MA,
USA), anti-NF-κB (p65) antibody (1:1000, Cell Signaling,
Boston, MA, USA), anti-NF-κB (p52) antibody (1:1000, Cell
Signaling, Boston, MA, USA), anti-β-Actin antibody (1:1000,
Cell Signaling, Boston, MA, USA), anti- GAPDH antibody
(1:2000, ZSGB-Bio, China), anti-PKD (1:500, Cell Signaling,
Boston, MA, USA), anti-phospho-PKD (1:250, Cell Signaling,
Boston, MA, USA), anti-CaMKII (1:500, Cell Signaling, Boston,
MA, USA), anti-phospho- CaMKII (1:250, Cell Signaling,
Boston, MA, USA) overnight, respectively. Membranes
were washed, followed by incubation with goat anti-rabbit
horseradish peroxidase-conjugated IgG (1:5000, abbkine)
at room temperature for 1 h. Proteins were detected using
Chemiluminescent HRP Substrate (Advansta) and visualized
with the ECL detection system (Bio-Rad, Berkeley, CA, USA).
The bands were measured by Gel-Pro Analyzer software (Media
Cybernetics, Rockville, MD, USA).
Quantitative Real-Time PCR
Total RNA was isolated using E.Z.N.A.rTotal RNA Kit I
(OMEGA) and analyzed on the NanoDrop2000c analyzer
(Thermo Scientific, Wilmington, DE, USA). Reverse
transcriptase reactions were performed using Revert Aid First
Strand cDNA Synthesis Kit (Thermo Scientific, Wilmington,
DE, USA). The primer sequences were synthesized by Invitrogen
and were designed as previously described (Sha et al., 2012). 18s
RNA was used as an internal control. qPCR was performed using
TransStart Top Green qPCR SuperMix (TransGen Biotech,
China) on the Stratagene Mx3000p PCR machine (Agilent
Technologies, Santa Clara, CA, USA).
Culture of Rat Neural Stem Cell Line
Rat fetal NSCs were purchased from Gibco Co. The cells
were plated in growth medium consisting of KnockOutTM
D-MEM/F-12 with StemPror Neural Supplement, bFGF, EGF
and GlutaMAXTM-I and incubated at 37◦C, 5% CO2 and 90%
humidity. Neurospheres were observed within the first week and
the medium was changed every 3–4 days. NSCs were passaged
when spheres reached the size of 3.5 mm. NSCs were transiently
transfected with corresponding plasmids using Lipofectamine
3000 for 48 h. The transfection efficiency was evaluated by flow
cytometry.
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Immunofluorescence
The wistar rats were perfused with 4% paraformaldehyde in
PBS and brains were postfixed in the same fixative for 24 h
and cryoprotected in 30% sucrose before vibratome sectioning
(40 µm, Leica CM1950). All experiments were performed in
accordance with the 1996 National Institutes of Health Guide for
the Care and use of Laboratory Animals, and the experimental
procedures were approved by the Local Committee of Animal
Use and Protection. Free-floating sections were permeabilized
with 0.2% TritonX-100 in PBS for 15 min, blocked in PBS
containing 5% donkey serum for 1 h at room temperature
and then incubated with anti-NPAS3 (1:100, Santa Cruz, CA,
USA) and anti-VGF (1:200, Abcam, Cambridge, MA, USA)
overnight at 4◦C. the sections were washed in the PBS and
incubated with fiuorescent secondary antibodies, donkey anti
rabbit conjugated with Alexa Fluor 488 (1:1000; Invitrogen)
and donkey anti goat conjugated with Alexa Fluor 594 (1:1000;
Invitrogen), for 1 h at room temperature. DNA (nuclei) was
stained with Dapi for 15 min, and mounted onto slides
and coverslipped with ProLong (Invitrogen). The images were
captured using the Olympus system and analyzed with the
ImageJ software.
Cell Proliferation Assay
The SH-SY5Y and PC12 cells were plated in 96-well plates in
1640 medium containing 10% FBS or 10% horse serum and 5%
FBS at a density of 1 × 105 cells each well and then transfected
with NPAS3, shRNA for NPAS3, siRNA for VGF, NPAS3 plus
siRNA for VGF, mock siRNA for VGF for 48 h. A 10-µL volume
of the Vita-Orange (WSTr-8; Biotool, USA) was then added to
each well and the cells were cultured for another 2 h. The plates
were then examined in a spectrometer at 450 nm to obtain the
absorbance (OD value) of each well.
Statistical Analysis
SPSS (IBM, Armonk, NY, USA) software was used for analysis.
Prism 5 software (GraphPad, San Diego, CA, USA) was used to
create the graphs. All experiments were repeated at least three
times. Data were presented as means ± standard deviation and
analyzed using two-tailed Student t-test or one way analysis of
variance (ANOVA) followed by Turkey or Dunnett T3 post hoc
tests for multiple comparisons.
RESULTS
Correlation Between NPAS3 and VGF in
Rat Neural Stem Cells
Our previous microarray analysis suggested that VGF is a highly
up-regulated gene by NPAS3 in 293T cells (Sha et al., 2012).
Expression of VGFwas examined at transcriptional (qPCR assay)
and at translational level (Western blotting) by manipulating
the expression of NPAS3 in NSCs. The mRNA (Figure 1A)
of VGF was significantly increased in NPAS3 overexpressing
NSCs (P = 0.007) and decreased in NPAS3 knockdown NSCs
(P = 0.003). Results of Western blots showed that VGF
exhibited a parallel response to NPAS3 in NSCs (Figures 1B,C;
pcDNA3.1 vs. NPAS3 P = 0.000, non-specific shRNA vs.
shRNA P = 0.004). The expression of Npas3 and Vgf in the
rat hippocampus was investigated using immunofluorescence
microscopy. Npas3 is expressed in the subgranular zone of the
dentate gyrus with processes radiating into the granule cell
proper (Figure 1D). Vgf was co-stained with Npas3 in the rat
hippocampus. Vgf was found to colocalize with Npas3, which
suggests that Npas3 might exert its function at the same process
in the hippocampus.
VGF Promoter can be Regulated by
NPAS3 in Various Cell Lines
In the light of our findings that VGF exhibited a parallel
response to NPAS3 in various cell lines, we hypothesized that
NPAS3 regulates VGF at the promoter level. 293T (Figure 2A),
SH-SY5Y (Figure 2B) and U251 (Figure 2C) cell lines were used
to examine the VGF promoter activity. The reason for choosing
293T cell line is that the behavior of the cell itself is not of interest
and 293T is a very good model for analyzing transcription of
a specific gene and widely used for neuronal study (Thomas
and Smart, 2005). Dual luciferase assay results showed that
activation of VGF promoter was significantly increased due
to over expression of NPAS3 (293T: pcDNA3.1 vs. NPAS3
P = 0.000; SH-SY5Y: pcDNA3.1 vs. NPAS3 P = 0.001; U251:
pcDNA3.1 vs. NPAS3 P = 0.000) and markedly reduced in
NPAS3 down-regulated cells (293T: non-specific shRNA vs.
shRNA P = 0.000; SH-SY5Y: non-specific shRNA vs. shRNA
P = 0.000; U251: non-specific shRNA vs. shRNA P = 0.000).
These findings suggested that VGF could be regulated by
NPAS3 at the promoter level.
Identification of Potential Regulatory
Domains Within NPAS3 Protein
We first compared the regulation of VGF by full-length (NPAS3)
and truncated NPAS3 (dNPAS3; Figure 3A), lacking the second
PAS domain and the putative transactivation domain, using
qPCR. As shown in Figure 3B, VGF gene showed a much more
robust up-regulated response in NPAS3 over expressed SH-SY5Y
cells (one way ANOVA P = 0.000, post hoc analysis: control vs.
dNPAS3 P = 0.000; control vs. NPAS3: P = 0.000; dNPAS3 vs.
NPAS3: P = 0.000). Then, Dual luciferase assays were carried out
to examine the regulation of VGF by NPAS3 at the promoter
level (Figure 3C). We observed that the luciferase activity ofVGF
promoter was significantly increased by NPAS3 or dNPAS3 (one
way ANOVA P = 0.000, post hoc analysis: control vs. dNPAS3
P = 0.000; control vs. NPAS3: P = 0.000). However, NPAS3 shows
a stronger activation on VGF promoter than dNPAS3 (P = 0.000;
Figure 3C). Taken together, each motif in NPAS3 might be
involved in the regulation of VGF.
E-Box Within VGF Promoter is Not the Only
Regulatory Sequence for Activation by
NPAS3
The VGF promoter region contains several consensus motifs for
transcriptional regulators, such as a CCAAT box, various SP-1
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FIGURE 1 | Correlation of Neuronal PAS domain protein 3 (NPAS3) and VGF in rat neural stem cells. Expression of VGF was quantified after modulating the
expression of NPAS3 in neuronal stem cells (NSCs). ORF of NPAS3 was cloned in pcDNA3.1 and referred to as NPAS3. Small hairpin RNA (shRNA) specific
NPAS3 was cloned in pGPU-GFP-neo vector and referred to as shRNA. (A) Transcription of VGF in NSCs with pcDNA3.1/over expressed NPAS3
(NPAS3)/non-specific shRNA/down regulated NPAS3 (shRNA) by quantitative real-time PCR (qPCR). 18s RNA was used to normalize data from each sample and
values are expressed as fold-change in gene expression in comparison to the control samples, VGF value of control cells is supposed to be 1. (B) Protein expression
levels of VGF and NPAS3 in NSCs with pcDNA3.1/over expressed NPAS3 (NPAS3)/non-specific shRNA/down regulated NPAS3 (shRNA). (C) Densitometric analysis
of VGF expression from western results was measured by Gelpro software. Total protein was normalized to β-actin. All experiments were repeated independently
three times. Asterisks mean a significant difference at ∗∗P ≤ 0.01 or ∗∗∗P ≤ 0.001. Error bars represent SD. (Analyzed by two-tailed Student’s t-test). (D) Npas3 and
Vgf protein expression was examined using immunofluorescence of frozen rat brain sections. Anti-Npas3 was labeled with an Alex Fluor 594 conjugated secondary
antibody (red). Anti-Vgf antibody was labeled with an Alex Fluor 488 conjugated secondary antibody (green). Original magnification was ×200.
and AP-2 consensus binding sites, a cAMP-response element
(Possenti et al., 1992), a CREB binding sites (Bozdagi et al.,
2008), a putative silencer element and an enhancer box (E-box)
near the transcription start site (D’Arcangelo et al., 1996). As
we know that bHLH domain transcription factors (such as
NPAS3) bind specifically to E-box, it is highly possible that
NPAS3 might regulate VGF through binding to its E-box. To
test this hypothesis, a VGF promoter with a mutated E-box
(TACGTG; Figure 4B) was compared with wild type VGF
promoter (Figure 4A). As the mutated promoter without E-box
sequence could not be recognized by bHLH domain, it should
not be activated by NPAS3. Luciferase activity of VGF promoter
with the site-mutated E-box was found lower than wild type VGF
promoter (P = 0.000). This indicates that the E-box is partially
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FIGURE 2 | NPAS3 regulates VGF at the promoter level in several cell lines. The activity of VGF promoter was tested by dual luciferase reporter assay after the
cells transfected with over expressed NPAS3 (NPAS3) and shRNA for NPAS3 (shRNA) with their relative controls. Similar results were observed among selected cell
lines, either cells transfected with (A) embryonic kidney cells (293T) or (B) with neuroblastoma (SH-SY5Y cells) or (C) glioblastoma (U251 cells). The values represent
the percentage of the relative activities to the pRL-TK vector (mean ± SD). All experiments were repeated three times. Asterisks mean a significant difference at
∗∗P ≤ 0.01 or ∗∗∗P ≤ 0.001 (Analyzed by two-tailed Student’s t-test).
FIGURE 3 | Identification of potential regulation motifs within NPAS3 protein. To find out the regulatory motifs of NPAS3, a mutant NPAS3 was constructed
which had only complete basic helix-loop-helix (bHLH) domain. The transactivation domain and a portion of putative transactivation (PAS) domain was deleted from
NPAS3 open reading frame. (dNPAS3) refers to truncated form of NPAS3 cloned in pcDNA3.1, while (NPAS3) refers ORF of NPAS3 cloned in pcDNA3.1.
(A) Structures of NPAS3 and dNPAS3 protein. (B) Transcription of VGF in the pcDNA3.1/NPAS3/dNPAS3 over expressed SH-SY5Y cells by triplicated qPCR. 18s
RNA was used to normalize data from each sample and values were expressed as fold-change in gene expression in comparison to the control samples. The VGF
value of control cells is supposed to be 1. (C) Luciferase activity of VGF promoter in the pcDNA3.1/NPAS3/dNPAS3 vector over-expressed SH-SY5Y cells. The
values represent the percentage of the relative activities to the pRL-TK vector (mean ± SD). All experiments were repeated three times. Asterisks mean a significant
difference at ∗∗∗P ≤ 0.001 (Analysis of variance [ANOVA] followed by Turkey post hoc test).
responsible for mediating the NPAS3 activation of the promoter.
However, that fact that NPAS3 could still significantly activate
the mutated E-box promoter suggests the additional route of
VGF activation by NPAS3.
NF-κB is Involved in the Transcriptional
Regulation of VGF
In order to identify the potential indirect regulation of VGF
by NPAS3, a shorter VGF promoter lacking κB site (990 bp;
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FIGURE 4 | VGF promoters with mutated or wild type enhancer box
(E-box) are both activated by NPAS3. To confirm the activation of VGF
expression regardless of NPAS3 bHLH domain, a wild type as well as mutated
E-box region of VGF was studied with the help of luciferase reporter assay.
(A) Wild type VGF promoter with E-box sequence (CACGTG) activity was
analyzed by the ectopic expression of NPAS3 in 293T cells. (B) Mutant E-box
(TACGTG) sequence with VGF promoter was also checked for the luciferase
activity with the over-expression (NPAS3) as well with shRNA for NPAS3
(shRNA). All experiments were repeated three times. The values represent the
percentage of the relative activities to the pRL-TK vector (mean ± SD).
Asterisks mean a significant difference at ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001 (Analyzed
by two-tailed Student’s t-test).
5′-GGGRNW YYCC-3′, R = purines, N = any nucleotide,
W = adenine or thymine and Y = pyrimidine) was constructed.
Luciferase activity of this promoter was compared with wild
type promoter (1237 bp) in 293T cells with over expressed or
down regulatedNPAS3. Interestingly, our results showed that the
NPAS3 dependent activation of VGF promoter was decreased
in the absence of the κB site compared to wild-type promoter
(P = 0.001; Figure 5A). This finding suggests that the κB site also
contributes to NPAS3 activation of the VGF promoter.
To further reveal the role of NF-κB in this process,
expression of VGF (non-acronymic) and molecules involved
in NF-κB pathway were examined by western blotting in
PC12 cells. Expression of VGF is significantly up-regulated by
over-expression NPAS3 (P = 0.000) and slightly down-regulated
in knock-down NPAS3 PC12 cells (P = 0.04; Figures 5B,C).
Caffeic acid phenethyl ester (CAPE) is a well documented NF-κB
inhibitor at high concentrations (Natarajan et al., 1996). The
CAPE treatment significantly reduced VGF expression (DMSO
vs. CAPE P = 0.000) and blocked the effect of NPAS3 on
VGF (NPAS3 + DMSO vs. NPAS3 + CAPE P = 0.000).
The positive control, NPAS3 + DMSO, significantly enhances
expression of VGF relative to samples treated by DMSO or
inhibitor. P65 and p52 are members of NF-κB superfamily
and have been examined for transcriptional regulation of genes
involved in cell proliferation. P65 showed parallel changes with
NPAS3 in PC12 cells (Figure 5D). NPAS3 has no effect on
p52 expression in PC12 cells (Figure 5E). The altered level of
p65 induced by NPAS3 implies that NF-κB might be involved
in the transcriptional regulation of VGF by NPAS3.
The Effects of NPAS3 and VGF on Cell
Proliferation
VGF was reported to induce proliferation of neural progenitor
cells (Thakker-Varia et al., 2014). Based on the correlation of
VGF and NPAS3 described in this study, we supposed that
NPAS3 might play a role in cell proliferation. Thus, effects of
NPAS3 on cell proliferation in vitro were subsequently examined
(Figure 6). Cell number quantifications (cell validations) of
SH-SY5Y and PC12 cells with different treatments were
examined by Vita-Orange (WSTr-8). The effects of NPAS3 on
cell proliferation in PC12 (Figure 6B) and SH-SY5Y (Figure 6C)
cells are similar.
First, cell proliferation was significantly increased in
NPAS3 over expressed cells (SH-SY5Y: pcDNA3.1 vs. NPAS3
P = 0.018; PC-12: pcDNA3.1 vs. NPAS3 P = 0.036) and reduced
in NPAS3 knockdown cells (SH-SY5Y: non-specific shRNA
vs. shRNA for NPAS3 P = 0.033; PC-12: non-specific shRNA
vs. shRNA for NPAS3 P = 0.05). This reveals the proliferative
effects of NPAS3.Secondly, siRNA for VGF was used to detect,
whether NPAS3 exerts it proliferative function though VGF. The
validation of cells transfected by siRNA for VGF was decreased
when compared to cells transfected by non-specific siRNA,
but not enough to be considered as significant statistically.
There was no significant difference between the values of cells
transfected by non-specific siRNA and cells transfected by
NPAS3 plus siRNA for VGF. The reason for this could be the
increased cell proliferation induced by NPAS3 was corrected
by knocking down VGF. This indicates that VGF is involved in
the proliferation induced by NPAS3. Furthermore, our results
showed that cell proliferation was significantly increased by
transfecting NPAS3 plus siRNA for VGF compared with neural
cells transfected alone by VGF (siRNA; SH-SY5Y: P = 0.012;
PC-12: P = 0.044). This phenomenon may be due to two
possibilities. First, other NPAS3 targets, which are important
for cellular growth and proliferation, may be involved in the
proliferative effect of NPAS3 (Sha et al., 2012). The other
possibility is that the knocking down method is not effective
enough to eliminate VGF and so, NPAS3 still could enhance cell
proliferation through VGF.
Signaling Pathways Downstream of
NPAS3-Induced Cell Proliferation
As it was reported that VGF enhances the proliferation of
neurogenesis through glutamatergic pathways, we supposed that
NPAS3 might contribute proliferation of neural cells through the
same route. Therefore, we first determined if NPAS3 activates
downstream signaling molecules of two glutamate receptors,
NMDA receptors and mGluR5 in PC12 cells. Inhibitors of
NMDA receptors and mGluR5 were used to exploit the
association of NPAS3 with glutamatergic pathways. Previous
research demonstrated dizocilpine (MK801, 50 µM)’s potential
to exert its function as an antagonist to NMDA receptors (Wong
et al., 1986). 2-methyl-6-(phenylethynyl)-pyridine (MPEP, 100
µM) was used as an antagonist to mGluR5 (Gasparini et al.,
1999). Activation of NMDA receptors induces phosphorylation
of Ca2+/CaMKII (Krueger et al., 2010), whereas PKD is regulated
by mGluR5 and sustains its phosphorylation form (Bayer et al.,
2001).
As shown in Figure 7A the phosphorylation of PKD was
significantly enhanced upon ectopic expression of NPAS3
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FIGURE 5 | NF-κB is involved in the regulation of VGF by NPAS3. (A) Luciferase activities of VGF promoters (with κB/without κB site) in 293T cells with
pcDNA3.1/over expressed NPAS3 (NPAS3)/non-specific shRNA/down regulated NPAS3 (shRNA). The values were normalized by the relative activities to the pRL-TK
vector (mean ± SD). (B) Protein expression levels of VGF, p65 and p52 in PC12 cells with different treatment. (C) Densitometric analysis of VGF from western results
was measured by Gelpro software. (D) Densitometric analysis of p65, from western results was measured by Gelpro software. (E) Densitometric analysis of p52 from
western results was measured by Gelpro software. Each sample was normalized by β-actin and values are expressed as fold-change. All data were generated from
experiments repeated three times. Asterisks mean a significant difference at ∗P ≤ 0.05 or ∗∗P ≤ 0.01 or ∗∗∗P ≤ 0.001 (Analyzed by two-tailed Student’s t-test and
ANOVA followed by Turkey post hoc test).
(P = 0.000), whereas the NPAS3 over-expression could not
enhance the phosphorylation of PKD when mGluR5 was
inhibited by MPEP (P = 0.415). To further confirm the
participation of VGF in regulation of PKD via NPAS3,
p-PKD was observed on blots after treating PC12 cells with
VGF (siRNA) alone or along with overexpression of NPAS3
(Figure 7B). As can be seen, up-regulated expression of
NPAS3 could not facilitate the phosphorylation of PKD when
VGF expression was reduced (P = 0.306), which further
validated that NPAS3 can activate PKD via mGluR5 by
targeting VGF. Similarly phosphorylation of CaMKII was
also increased significantly on overexpression of NPAS3
(P = 0.000), whereas the increased expression of NPAS3 failed
to augment the phosphorylation of CaMKII in the presence
of NMDA inhibitor MK801 (P = 0.166; Figure 7C). Likewise
phosphorylation of PKD, CaMKII activation was also induced
by VGF, which was confirmed by using VGF (siRNA)
alone or with ectopically expressed NPAS3 (P = 0.147;
Figure 7D).
DISCUSSION
This study demonstrates that NPAS3 regulates transcription and
expression of VGF and delineates that NF-κB signaling pathway
is involved in this activation. In addition, this work clarifies
that NPAS3 enhances proliferation of neural cells through
VGF. This process requires synaptic activity. The signaling
molecules required for NPAS3-induced cell proliferation include
PKD and CaMKII through glutamate receptors, which were
reported to be involved in VGF-induced proliferation of
NSCs (Thakker-Varia et al., 2014). Revealing the regulation
of NPAS3 on VGF and the precise mechanism of how
NPAS3 influences neural cell proliferation will increase our
understanding of pathophysiological mechanisms of psychiatric
disorders.
To date, adult hippocampal neurogenesis has gained a great
deal attention for its potential implication in various psychiatric
disorders. Disruption of neurogenesis may reflect the latest stages
of a subtle misregulation of brain development and result in
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FIGURE 6 | Effect of NPAS3 and VGF on proliferation of neural cells. The effect of growth on SH-SY5Y and PC12 cells were assayed by modulating the
expression of NPAS3 and VGF, and examined by Vita-Orange (WSTr-8) dye. (A) Viability of SH-SY5Y and PC12 cells transfected by different factors examined by
Vita-Orange (WSTr-8) assays (OD values, mean ± SD). (B) Statistical analysis of OD values of SH-SY5Y cells transfected by different factors. (C) Statistical analysis
of OD values of PC12 cells transfected by different factors. All data was generated from four independent experiments. Asterisks mean a significant difference at
∗P ≤ 0.05 (Analyzed by two-tailed Student’s t-test and ANOVA followed by Turkey post hoc test). Vita-Orange (WSTr-8) assays on PC12 and SH-SY5Y cells have
similar results. Over expression of NPAS3 shows a significant enhancement on cell viability compared with control samples. Knocking-down of VGF results in a clear
decrease in cell viability compared with cells transfected with non-specific siRNA, but not enough to be considered as significant statistically. The viability difference
between control samples and cells transfected by NPAS3 plus siRNA for VGF was out of statistical significance (NS).
a particular set of hippocampal symptoms in schizophrenia
patients (Kempermann et al., 2008; Hill et al., 2015). However,
correlation of these two processes still remains unclear. This
study details how several pivotal factors involved in the process
of neurogenesis and also in the development of psychiatric
illnesses.
VGF was identified as one of the NPAS3 targets in our
previous study (Sha et al., 2012). In addition, VGF shares a
number of key features with NPAS3: regulation by circadian
rhythm (Cirelli and Tononi, 2000); involvement in metabolic
control (Altshuler and Hirschhorn, 1999; Salton et al., 2000;
Jethwa et al., 2007; Sadahiro et al., 2015); contribution to
activity-related adult neurogenesis (Thakker-Varia et al., 2007),
and association with neurological diseases (Ruetschi et al., 2005;
Selle et al., 2005; Pasinetti et al., 2006; Altar et al., 2009) and
psychiatric diseases, including schizophrenia (Huang et al., 2006)
and depression (Huang et al., 2006; Malberg and Monteggia,
2008; Thakker-Varia and Alder, 2009).
NPAS3 is a brain-enriched transcription factor containing
a bHLH motif at the amino terminus, followed by two
PAS domains. The carboxyl-terminal end contains a putative
transactivation domain. The bHLH domain contains the DNA
binding region, which typically binds to a consensus DNA
sequence (E-box, CANNTG; Chaudhary and Skinner, 1999).
The PAS domain includes two conserved regions (PAS-A and
PAS-B; Crews et al., 1988). Many PAS-domain proteins exert
their function by dimerization with another subunit, such
as NPAS3-BMAL1 complex. In this project, the correlation
of VGF by dNPAS3, a truncated form of NPAS3, was
compared with wild type NPAS3. dNPAS3 is a very good
model to study the function of individual domains of NPAS3,
as it is lacking the second PAS domain and the putative
transactivation domain. The transactivation activity of VGF
by dNPAS3 is much weaker than the wild type NPAS3. This
implicated that each motifs in NPAS3 is important for regulation
of VGF.
Our previous studies found location of NPAS3 in
hippocampus of adult mice and proposed that it might have
a role during neurogenesis (Sha et al., 2012). Furthermore,
in the current study, members of NF-κB family might be
regulated by NPAS3. The NF-κB family of transcription factors,
including p50, p52, RelA/p65, cRel and RelB, have been shown
to play important roles in hippocampal neurogenesis and
psychiatric disorders (Meffert et al., 2003; Crampton and
O’Keeffe, 2013; Bortolotto et al., 2014; Aloor et al., 2015; Malki
et al., 2015).
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FIGURE 7 | Activation of calmodulin-dependent protein kinase II (CaMKII) and protein kinase D (PKD) by NPAS3. (A) To decipher the signaling network by
which NPAS3 regulates the growth in neuronal cells in context to VGF, an expression of PKD and phospho-PKD was examined by using
2-methyl-6-(phenylethynyl)-pyridine (MPEP; mGluR5 inhibitor) in association with ectopic expression of NPAS3. Graphs represents densitometric analysis for the
expression of phopho-PKD with respect to endogenous PKD protein. It’s evident that the upregulated expression of NPAS3 in PC12 cells increased the
phosphorylation of PKD, which can be reverted by inhibiting the metabotropic glutamate receptor 5 (mGluR5) receptor. (B) Blocking the VGF expression via siRNA
inhibited the influence of NPAS3 on the phosphorylation of PKD, which confirms association of NPAS3 and VGF in context to neuronal signaling network. (C) Another
important glutametergic protein (CaMKII) was evaluated in association with the increased expression of NPAS3. The phosphorylation of CaMKII which is the
downstream molecule for N-methyl D-aspartate (NMDA) was significantly increased upon the overexpression of NPAS3, but NPAS3 effect on CaMKII was hampered
by inhibiting NMDA activity by MK801. Graphs represents densitometric analysis for the expression of phopho-CaMKII with respect to endogenous CaMKII protein.
(D) On treating the PC12 cells with VGF (siRNA), the CaMKII phosphorylation was significantly reduced, which also could not be compensated with over-expression
of NPAS3. Protein was extracted after 48 h of each mentioned transfection in the figure. Cultures were treated with different inhibitors mentioned above for 2 h before
collection. Bars represent means of protein expression relative to control ± SD (n > 3). Asterisks mean a significant difference at ∗P ≤ 0.05 or ∗∗P ≤ 0.01 or ∗∗∗P ≤
0.001 (Analyzed by two-tailed Student’s t-test and ANOVA followed by Dunnett T3 post hoc test). All data were generated from experiments repeated three times.
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FIGURE 8 | Proposed NPAS3 regulation of VGF. A potential network was proposed based on published information and our findings. NPAS3 activates VGF
through not only binding to its E-box, but also through κB site by regulating NF-κB channel. Besides the κB sites, other elements in VGF promoter might be indirectly
involved in the regulation of NPAS3 as well. Various NF-κB transcriptional targets, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF),
could regulate VGF by binding to specific sites. Phosphorylation of CaMKII and PKD could be activated by NPAS3- VGF through NMDA receptors and mGluR5,
respectively. In this network, BDNF and NGF are upstream of VGF and also highly associated with psychiatric disorders and neurogenesis.
Combining our work and previously published literature, a
potential network intersecting the processes of neurogenesis and
psychiatric disorders was proposed (Figure 8). NPAS3 might
regulate VGF not only through E-box, but also through κB
site. Besides the κB site, other elements in VGF promoter
might be indirectly involved in the regulation of NPAS3 as
well. As known, Various NF-κB transcriptional targets, such as
Brain-Derived Neurotrophic Factor (BDNF) and Nerve growth
factor (NGF; Zaheer et al., 2001; Krock et al., 2016), could
regulate VGF (Thakker-Varia and Alder, 2009). Thus, NF-κB
(p65) may regulate VGF in part by binding to κB site as well as
by modulating BDNF and NGF. Thus, NPAS3, NF-κB, BDNF
and NGF are upstream molecules of VGF. Phosphorylation
of CaMKII and PKD could be activated by NPAS3-VGF
through NMDA receptors and mGluR5, respectively. PKD and
CaMKII are downstream of mGluR5 and NMDA receptors.
PKD, a serine threonine kinase, is involved in promoting DNA
synthesis and cell proliferation in different cells (Wong and
Jin, 2005). CaMKII has an important role during maturation
of granule cells in the dentate gyrus (Yamasaki et al.,
2008). Activation of CaMKII produces increased neurogenesis
and LTP in olfactory bulbectomized mice (Moriguchi et al.,
2013).
In this network, BDNF and NGF are upstream of VGF and
highly associated with psychiatric disorders and neurogenesis.
Neuropeptide VGF and BDNF are intrinsic factors that
induce neurogenesis and enhance synaptic activity of
hippocampal neurons (Alder et al., 2003). VGF is identified
as an NGF-responsive gene and they are involved in many
processes in the brain (Levi et al., 2004; Ferri et al., 2011).
Therefore, NPAS3 and VGF might function to orchestrate the
molecular response during the processes of neurogenesis and
psychiatric disorders. This work is consistent with previous
reports (Sha et al., 2012) and intersects psychiatric candidate
genes and molecules involved in neurogenesis and synaptic
activity. However, although we have verified the connection
of NPAS3 and VGF in neural cell lines, how NPAS3 and VGF
influence neurogenesis at different phases need to be further
studied in animal models and NSCs.
Understanding the correlation of these factors and how they
contribute to the neurogenesis and synaptic activities might shed
a light on antidepressant therapies. The neurotrophic/plasticity
hypothesis of depression has been proposed more than a decade
ago (Duman et al., 1997) and has been supported by multiple
basic and clinical studies (Duman et al., 1999; Czeh et al.,
2001; Madsen et al., 2003; Sahay and Hen, 2007; Mostany
et al., 2008; Li et al., 2010). Recent antidepressant compounds,
aiming at new targets and cascades associated with neurotrophic
mechanism were developed. Agomelatine, a melatonergic analog
drug acting as melatonin agonist and a 5-hydroxytryptamine
(5-HT)2C antagonist (Millan et al., 2003), is of particular
interest due to its efficacy, safety and tolerability. It has been
demonstrated to enhance proliferation and neurogenesis in the
ventral dentate gyrus under basal conditions (Banasr et al., 2006;
Soumier et al., 2009). Another neuroprotective compound, P7C3,
exerts its antidepressant effect through enhancing hippocampal
neurogenesis (Walker et al., 2015). Prolonged administration of
P7C3 to NPAS3 −/− mice corrected deficits in hippocampal
neurogenesis andmalformation and dysfunction of dentate gyrus
(Pieper et al., 2010).
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The antidepressant properties of Agomelatine have been
reviewed by Pompili et al. (2013). Agomelatine has a rapid
antidepressant actions and good tolerability in most clinical
trials. It facilitates all stage of neurogenesis and promotes cell
survival in the ventral hippocampus through the combination of
activation of MT1/MT2 melatonergic receptor and the blockade
of 5-HT2C receptors after chronic administration (Banasr et al.,
2006; Soumier et al., 2009). Furthermore, BDNF, ERK1/2, Akt
and GSK3β have been reported to participate in the induction of
hippocampal neurogenesis by agomelatine (Banasr et al., 2006;
Conboy et al., 2009; Soumier et al., 2009; Molteni et al., 2010).
Therefore, agomelatine may be considered as an interesting
and valid treatment option given its potential in neuroplasticity
mechanisms.
Although schizophrenia and major depression are not
specifically hippocampal disorders, adult neurogenesis might
be involved in hippocampal aspects of psychiatric disorders
(Kempermann et al., 2008). Adult neurogenesis can be activated
by several physical and chronic antidepressant treatments
(Warner-Schmidt and Duman, 2006). Decreased progenitor
cell proliferation in adult dentate gyrus in schizophrenia was
reported (Reif et al., 2006). A better understanding of the
regulation of neurogenesis by psychiatric candidate genes
may yield insights into the discovering of more selective
targets. Several molecules relevant to pathophysiology of
depression, including BDNF, ERK1/2, Akt and GSK3β, could be
modulated by agomelatine. As known, VGF could be regulated
by BDNF and PI3K/AKT/mTOR signaling (Lu et al., 2014).
Whether agomelatine will be efficient in major depressive and
schizophrenic patients with abnormal expression of VGF needs
to be further examined. In addition, NPAS3 knockout mice also
display an additional deficit in adult hippocampal neurogenesis
and aberrations in synaptic transmissions (Pieper et al., 2005,
2010). Results of this study suggest that NPAS3 enhances
proliferation of neural cells through VGF. It remains to
be discovered whether NPAS3−/− mice have disturbances
at the signaling pathways which are agomelatine targets.
Furthermore, identification of neuroprotective compounds
which could overcome the deficits in hippocampus of
NPAS3−/− mice will surely be of value in the development
of treatments for psychiatric patients with abnormal expression
of NPAS3.
In conclusion, the discovery and understanding of the
psychiatric candidate genes will provide novel cellular targets for
development of safer, more efficient treatments. The findings
in this study indicate a correlation between NPAS3 and VGF,
and propose a potential network composed by NPAS3, VGF
and several other pivotal factors relevant to neurogenesis and
psychiatric disorders. Furthermore, this study demonstrates
that NPAS3 enhances cell proliferation through glutamatergic
pathways via VGF.
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